Multiple systemic metastases of posterior fossa-primitive neuroectodermal tumor (PF-PNET) in adult - Case report by Mattos, JP et al.
Arq Neuropsiquiatr 2003;61(1):100-103
MULTIPLE SYSTEMIC METASTASES OF POSTERIOR
FOSSA - PRIMITIVE NEUROECTODERMAL TUMOR
(PF-PNET) IN ADULT
Case report
João Paulo Mattos1, Leonardo Bonilha2, Daniele Ferreira3, Wilson Borges1,
Yvens Barbosa Fernandes4, Guilherme Borges5
ABSTRACT - We present the case of a 30-year female patient with multiple systemic metastases of posterior
fossa primitive neuroectodermal tumor (PF– PNET) and present a review concerning the usual presentation,
sign and symptoms, radiological aspects, pathways of spread, genetic patterns and treatment of PF-PNET. The
biological behavior of PF - PNET is analyzed taking into consideration the presence of systemic metastases.
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Metastases sistêmicas múltiplas de tumor neuroectodérmico primitivo (PNET) na fossa posterior em
adulto: relato de caso
RESUMO - A presença de metástases múltiplas sistêmicas decorrentes de um tumor neuroectodérmico primitivo
(PNET) numa paciente de 30 anos é relatada. É feita pelos autores revisão desta patologia, incluindo sua
apresentação clínica, sinais e sintomas, aspectos radiológicos, vias de disseminação, aspectos genéticos e
tratamento. É abordado na discussão do caso particularmente o comportamento metastático dos medulo-
blastomas, comparativamente com os não metastatizantes.
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The term medulloblastoma was coined by Bailey
and Cushing in 19251 after the observation of ma-
lignant midline tumors of posterior fossa with unique
features. Hart and Earle in 19732 used the term pri-
mitive neuroectodermal tumor ( PNET ) during the
description of supratentorial tumors with small,
round and blue cells. Rorke in 19833 described that
these cells observed in supratentorial tumors were
undistinguishable from those observed in medullo-
blastomas. The World Health Organization, after
that, formally introduced the term posterior fossa –
primitive neuroectodermal tumor (PF–PNET) for Me-
dulloblastomas. In 1936, Nelson4 reported the first
case of metastases of medulloblastoma outside the
Central Nervous System (CNS). Thereafter, some re-
ports of spread outside of the CNS of PF - PNET have
been published, and most of them in pediatric popu-
lation. PF–PNET represents about 15 to 30 % of
childhood brain tumors5-8. The frequency in the adult
population ranges from 1% to 2% among CNS tu-
mors6-8. Metastases outside the CNS are rare. The
overall incidence of non-CNS involvement by PF -
PNET comprises approximately 7%8-9.
We present a case of multiple systemic metastases
of a PF – PNET in a female adult patient, and a lite-
rature review.
CASE
A 30-year female patient presented as an outpatient
to the University Hospital complaining of generalized bone
pain. Her physical examination upon arrival was unremar-
kable and laboratory evaluation showed mild anemia, ele-
vation of sedimentation rate and hypercalcemia. She had
a medical history of resection of a medulloblastoma per-
formed four years before. One year after the first surgical
approach, local recurrence occurred and another gross to-
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Fig 1. Absence of intracranial recurrence of the medulloblastoma
in a postoperative axial CT scan with contrast enhancement.
Fig 2. Sagittal T2-weighted MRI of the spinal cord showing an
extensive intra-axial metastasis. (A = anterior).
tal resection of the cerebellar tumor was done, followed
by posterior fossa radiotherapy performed with 56 Gy and
craniospinal axis radiotherapy with 36 Gy.
She continued to be followed in the outpatient clinic
and two months later she presented at emergency room
with poor general status, dyspnea, lumbar pain and pro-
gressive paraparesis with sphincter disturbance, and pyra-
midal signs in both lower extremities. Her clinical exami-
nation also revealed a hard nodule at eleventh left rib. It
was not possible to define then a spinal cord level of sen-
sitive deficit. X- Ray evaluation showed extensive bilateral
pleural effusion and blastic lesions at ribs and vertebral
bodies. The suspicion of bone metastases was enhanced
by osseous radionuclide study. Thoracentesis fluid analysis
was positive for malignant cells. Brain imaging did not
show local posterior fossa or supratentorial recurrence (Fig
1). The spinal cord Magnetic Resonance (MR) study showed
multiple lesions compressing the spinal cord from T3 to
T11, lesions at paravertebral musculature, pleural and lung
nodules (Figs 2 and 3). She was submitted to additional
spinal axis radiation therapy (0,8 Gy) but a complete sen-
sitive, motor and sphincter deficit developed in spite of
the treatment. A bone excision biopsy was performed con-
firming undifferentiated small malignant cells with tumor
markers compatible with medulloblastoma ( Sinaptofisin
+, GFAP +, Vimentin +, S100 -, LCA -, AE1AE3 -, Neuro-
philaments - ). Due to her bad clinical status, chemothera-
peutic regimen was not performed and the patient died
two months later.
DISCUSSION
PF – PNET is a rare tumor in adult patients and
systemic metastases are even rarer. The PF - PNET
has a male preponderance 2:16,10 and the average
age of presentation is between 24 - 34 years when
the tumor occurs in adults6,8,9. Headache is the most
common symptom, followed by ataxia6. Papiledema,
nauseas, vomiting, cranial nerve palsies, blurred
vision and mental changes are also found. When
extra cranial metastases are present, hypercalcemia,
thoracic or abdominal pain, dyspnea and bone nodu-
le are the most prominent features.
Bone is a frequent site for PF - PNET systemic me-
tastases11-13 and blastic lesions are the most frequent
radiological pattern14. Lymph nodes, lungs, abdomi-
nal cavity, breast and pancreas are also sites of PF -
PNET spread outside the CNS15,16. Different pathways
of spread of PF - PNET cells have been postulated
since different organs have been described as harbo-
ring metastases. The possible routes for dissemi-
nation are lymphatic vessels, cerebrospinal fluid in
the sites where nerve fibers leave the CNS, and blood,
through arachnoid villi and the increased blood brain
permeability9,10,17.
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Surgery has been cited as a pathway for disse-
mination since the lumen of blood vessels is exposed
and tumor cells may be carried to distant sites. Ventri-
cle Peritoneal shunt (VP-shunt) is described as
another pathway for dissemination of tumor cells.
These observations are based on numerous publi-
cations reporting the greater incidence of metastases
in patients who undergo surgery10,17 or VP-shunt9.
However, several reports considered the dissemina-
tion through surgery or VP-shunt questionable, since
regardless of whether the surgical procedure was
performed, the location of extraneural metastases,
incidence and the time of appearance of systemic
disease are the same. This suggests that both the sur-
gery and insertion of VP-shunt do not increase the
likelihood of an unfavorable prognosis due to systemic
metastases7. Complete tumor resection decreases the
frequency of local recurrence, however a relationship
between the extent of surgical resection and
extraneural metastases has not been found5,7.
The gene expression of the PF - PNET that metas-
tasizes is probably different from the gene expression
of the PF - PNET that is restricted to the cerebellum.
This is a possible explanation of the presence of sys-
temic metastases in some patients, irrespective of
the treatment applied, age of the patient, extent of
tumor resection, sex and the presence of VP shunt7.
Platelet – derived growth factor receptor alpha
(PDGFRA) and members of the downstream RAS /
mitogen – activated protein kinase (MAPK) signal
transduction pathway are up regulated in metastatic
PF - PNET, and may act as therapeutic target along
with HAS proteins and PDGFRA inhibitors18. The pre-
sence of the iso (17q) chromosome has also been
reported as prognostic factor19.
The treatment of the PF – PNET requires surgical
resection as complete as possible and the rational
use of radiation and chemotherapeutic drugs as an
adjuvant therapy. There are many regimens for ra-
diation therapy ( XRT ). Posterior fossa doses are
defined around 55 Gy and craniospinal axis doses
around 30 Gy (20) and 35 Gy21-23. Radiation therapy
is recommended for all patients after surgical pro-
cedure as prophylactic treatment to prevent local
and distant CNS recurrence.
The benefits of chemotherapy are yet to be
straightforwardly defined, as compared to radiation
therapy. Studies addressed to evaluate chemotherapy
have used different classifications for low and high
risk patients and the groups of patients have not
been uniform. However, there is a tendency towards
the use of a combination of Vincristine, CCNU, pred-
nisone, procarbazine and methotrexate16,21,22,24 for
rescue therapy or for high risk patients. This includes
those with distant metastases, bone marrow tumoral
cells, spinal seeding and VP shunt. Unfortunately,
intensive chemotherapeutic regimens fail to show
positive effects and eventually replace or diminish
XRT16,21,22 in order to lower its side effects especially
in children.
Fig 3. Axial T1-weighted image showing a large right pulmonary (thick arrow), vertebral body (arrow head), left
rib (curved arrow), and intra-axial metastases (dotted-line arrow). (R = right).
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The chance of cure for PF – PNET has improved in
the last decades16,25. A five year survival has increased
from previous reports of approximately 50%5 to
recent reports showing a higher range (50 to 80%)
for a bigger time span (ten years)16,23. The reasons
for the increase in survival rates are due to more
complete surgical resection achieved with microo-
perative techniques, along with the rational use of
chemotherapy and radiation therapy.
Systemic metastases constitute a rare compli-
cation of PF - PNET, that changes the outcome and
are an obstacle to long term survival. Prevention to
local and CNS recurrence is possible and usually per-
formed. The presence of distant metastases, howe-
ver, is difficult to avoid with our current therapy8,16.
Further studies on molecular biology and the gene
expression of the PF - PNET may shed light on the
biological properties of the tumors that metastasize
and the comprehension of the pathophysiology may
guide new forms of treatment.
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